Circulating Tumor DNA Predicts the Response and Prognosis in Patients With Early Breast Cancer Receiving Neoadjuvant Chemotherapy

PURPOSE: Many patients with breast cancer still relapse after curative treatment. How to identify the ones with high relapse risk remains a critical problem. Circulating tumor DNA (ctDNA) has recently become a promising marker to monitor tumor burden. Whether ctDNA can be used to predict the respons...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Shunying, Lai, Hongna, Liu, Jieqiong, Liu, Yujie, Jin, Liang, Li, Yudong, Liu, Fengtao, Gong, Yuhua, Guan, Yanfang, Yi, Xin, Shi, Qianfeng, Cai, Zijie, Li, Qian, Li, Ying, Zhu, Mengdi, Wang, Jingru, Yang, Yaping, Wei, Wei, Yin, Dong, Song, Erwei, Liu, Qiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2020
Materias:
Original Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7450928/
https://www.ncbi.nlm.nih.gov/pubmed/32923909
http://dx.doi.org/10.1200/PO.19.00292

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7450928/
https://www.ncbi.nlm.nih.gov/pubmed/32923909
http://dx.doi.org/10.1200/PO.19.00292

Ejemplares similares